A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur
A phase 3 trial of Camrelizumab, Rivoceranib in hepatocellular carcinoma, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation is a phase 3 interventional study registered as NCT04639180 by Jiangsu HengRui Medicine Co., Ltd., with 687 participants enrolled, started 2021-04-01 and due to reach its primary completion in 2026-07-31. Interventions recorded: Camrelizumab, Rivoceranib (Apatinib). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Hepatocellular carcinoma.
- TrialStudy to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
- PersonPiaoyang Sun
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
- TrialCamrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
- TrialCARES-310
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Hepatocellular carcinoma.
- TrialCameL
- TreatmentCamrelizumab + rivoceranib
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Hepatocellular carcinoma.
- PersonShukui Qin